Spyre Therapeutics, INC Schedule 13G passive stakes

Perceptive Advisors LLC, along with affiliated entities, has reported a beneficial ownership of 4.9% in Spyre Therapeutics, Inc., holding 4,319,496 shares.

RTW Investments, LP and Roderick Wong have disclosed a beneficial ownership of 4,251,996 shares, representing 4.8% of Spyre Therapeutics, Inc.'s common stock.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported beneficial ownership of 5.0% of Spyre Therapeutics, Inc.'s common stock as of April 15, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Spyre Therapeutics Inc. following an internal realignment.

The Vanguard Group has reported a 5.08% beneficial ownership stake in Spyre Therapeutics Inc., holding over 3 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in SPYRE THERAPEUTICS INC's common stock.

Tang Capital Management, Kevin Tang, and affiliated entities have disclosed a passive 5.3% beneficial ownership stake in Spyre Therapeutics, Inc., totaling 3,200,000 shares of common stock.

Venrock Healthcare Capital Partners and affiliated entities have filed an amendment to their Schedule 13G, disclosing a collective beneficial ownership of 4.6% in Spyre Therapeutics, Inc. as of December 31, 2024.

Perceptive Advisors LLC and its affiliates have reduced their beneficial ownership in Spyre Therapeutics, Inc. to 4.4% of the common stock, as disclosed in a recent SEC Schedule 13G/A filing.

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a 6.2% beneficial ownership stake in Spyre Therapeutics, Inc. as of December 31, 2024.